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Introduction
• Persistent Human Papilloma Virus infection is a necessary 
cause of cervical cancer, the second leading cause of 
cancer death in women worldwide with 450,000 new cases 
each year
• Two very effective preventive vaccines are now available.
• Still as 100’s of million women are already infected or will 
become infected in the future, as the vaccine is expensive 
and not yet widely applicable and as the preventive 
vaccines’ effects will take decades to materialize in lower 
rates of cervical cancer there is a medical need for 
therapeutic vaccines that work after HPV infection or lesion 
development
• HPV can also be a showcase for the demonstration of the 
effects of therapeutic vaccines
Therapeutic HPV vaccines in 
development
• There are about a dozen biotech companies 
involved in therapeutic HPV vaccines based 
on peptide, protein or DNA technology and 
administered through a variety of delivery 
platforms ranging from liposomes, 
adjuvants, in vivo electroporation, gene 
guns through viral and bacterial vectors.   
• Replicons based on Venezuelan Equine 
Encephalitis Virus
• Recombinant RNA vectors based on 
Vesicular Stomatitis Virus
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• RNA format- no risk of integration
• Apoptosis induction
• Replication incompetent vector (no spreading)
• No widespread pre-existing immunity in humans
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Stomatitis Virus (VSV)
-Single linear negative sense ssRNA genome with cytoplasmic 
replication
-Attenuated with mutations to limit nucleocapsid formation (N4 
Shuffle) reduce particle assembly and pathogenicity (G-CT9 
truncation)
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Therapy of day 5 established murine C3.43 tumors by 
homologous or heterologous prime/boost
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Immunogenicity study design for prime/boost vaccination 
in Rhesus macaques (n=6/group)
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Conclusions
• HPV 16 and 18 E6 and E7 antigens are immunogenic
• VRP/VSV heterologous vaccination in non-human 
primates is dramatically more immunogenic than 
homologous vaccination with either vector alone.
• Heterologous vaccination in mice with VRP and VSV 
vectors expressing HPV antigens induces robust T cell 
immunity that is efficacious in both prophylactic and 
therapeutic tumor models.
Prostate cancer prevention/therapy through 
vaccination
• Prostate cancer is the second-leading cause of cancer-related 
death in males 
• Patients who relapse after surgery or radiation therapy may be 
treated with androgen ablation, but its effects lasts less than 18 
months. Most patients develop hormone-refractory prostate cancer 
and die within 12 months
• Chemotherapy is effective but long-term chemotherapy is not 
feasible due to its toxicity 
• Currently, therapeutic options are very limited for advanced cases
• Therapeutic vaccines might be an option to prevent or treat 
localized and metastatic disease
Prostate (cancer) associated antigens
• PSA, prostate specific antigen
• PSMA, prostate specific membrane antigen
• PSCA, prostate stem cell antigen
• PAP, prostatic acid phosphatase
• STEAP, six transmembrane epithelial 
antigen of the prostate
• Sperm fibrous sheet proteins
Vaccination strategies chosen
• Prime / boost with heterologous vaccines
• DNA by gene gun followed by VRP (Venezuelan equine encephalitis 
virus replicons, alpha virus)
• Alpha virus replicons have been shown to break tolerance to self 
antigens
• VRP have been in the clinic for HIV trials
• Unique access to VRP with  STEAP and PSCA through Alphavax
Prostate Cancer Models
• Male C57 Bl/6 mice challenged with TRAMP-C2 
prostate cancer cells
• Male TRAMP mice are transgenic for SV40T under 
control of the probasin promoter and develop 
neuroendocrine prostate carcinomas
• CPP (PTEN KO) mice that develop prostate 
adenocarcinomas  
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mSTEAP vaccination with androgen ablation 
improves survival in tumor-bearing TRAMP mice
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Conclusions
• There are several prostate antigens that can 
induce T cell immunity without measurable 
autoimmune side effects
• Our vaccination data in the TRAMP model show 
spectacular lifelong survival outcomes. This might 
induce a paradigm shift in how we would handle 
prostate cancer in patients by using therapeutic 
vaccines in the preventive setting rather than 
aggressive treatments
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